Within the framework of the investigation launched on Menarini Sağlık ve İlaç Sanayi Ticaret AŞ and on Genveon İlaç Sanayi ve Ticaret AŞ with the Competition Board decisions dated 09.11.2023, numbered 23-53/1004-M and dated 21.02.2024, numbered 24-09/165-M, respectively, in order to determine if they violated Article 4 of the Act no 4054 on the Protection of Competition (act no 4054), in response to the settlement texts submitted by Menarini Sağlık ve İlaç Sanayi Ticaret AŞ and Genveon İlaç Sanayi ve Ticaret AŞ with regard to the interim decisions of the Board, it was decided that,

• Menarini Sağlık ve İlaç Sanayi Ticaret AŞ engaged in the exchange of competitively sensitive information with its competitor, thus violating Article 4 of the Act no 4054 and therefore should be imposed an administrative fine of 42,148,808.07 TL,
• Genveon İlaç Sanayi ve Ticaret AŞ entered into agreements/concerted practices with its competitors by concluding gentlemen’s agreements not to employ personnel from each other in the labor market, thus violating Article 4 of the Act no 4054 and therefore should be imposed an administrative fine of 35,722,195.45 TL,

thereby terminating the ongoing investigation with a settlement for the aforementioned undertakings.

As known, under the same investigation, administrative fines of 33,321,564.11- TL, 184,363,976.71- TL, 155,488,332.29- TL and 30,593,234.79- TL were previously imposed on GlaxoSmithKline İlaçları Sanayi ve Ticaret AŞ, Abdi İbrahim İlaç Sanayi ve Ticaret AŞ, Bilim İlaç Sanayii ve Ticaret AŞ and Drogsan İlaçları Sanayi ve Ticaret AŞ respectively, and the investigation was terminated with a settlement for the aforementioned undertakings.